Tvardi Therapeutics, Inc.
TVRD
$1.85
-$0.09-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -254.96% | 28.97% | 42.75% | -0.25% | 159.74% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.82% | -93.58% | -83.69% | 249.47% | -12,955.32% |
| Change in Net Operating Assets | -254.74% | 115.46% | -78.75% | 172.48% | -51.52% |
| Cash from Operations | -57.26% | 23.80% | -17.63% | 36.03% | -119.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 153.84% | 145.72% | -- | -- | -- |
| Cash from Investing | 153.84% | 145.72% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -2,964.29% | -- |
| Cash from Financing | -- | -- | -100.00% | -2,200.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.37% | 95.62% | -103.08% | 111.55% | 443.75% |